文献速递血栓与止血

福坦替尼治疗日本原发免疫性血小板减少症患者:一项3期、安慰剂对照、双盲、平行组研究

Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study.
PubMed 文献 · Br J Haematol · 2022-12-05

这项3期双盲安慰剂对照研究将34例日本原发免疫性血小板减少症患者随机分配至福坦替尼组(n=22)或安慰剂组(n=12),接受100-150 mg每日两次治疗24周。福坦替尼组8例(36%)达到稳定缓解,安慰剂组0例(p=0.030);总缓解分别为10例(45%)和0例(p=0.006)。福坦替尼组救援药物使用更少、出血症状更少,不良事件为轻至中度且可控。

要点

  • 福坦替尼组稳定缓解8例(36%),安慰剂组0例(p=0.030)。
  • 福坦替尼组总缓解10例(45%),安慰剂组0例(p=0.006)。
  • 福坦替尼组救援药物使用更少、出血症状更少,不良事件为轻至中度且可控。

核心结论

  • 福坦替尼在日本原发免疫性血小板减少症患者中显示出疗效,未发现新的安全性信号。

研究设计与样本

  • 3期、安慰剂对照、双盲、平行组研究,34例日本原发免疫性血小板减少症患者随机分配至福坦替尼组(n=22)或安慰剂组(n=12)。
  • 给药方案为100-150 mg每日两次,治疗24周。

主要发现

  • 稳定缓解(第14至24周6次访视中至少4次血小板≥50000/μl)福坦替尼组8例(36%)vs 安慰剂组0例(p=0.030)。
  • 总缓解(第2至12周6次访视中至少1次血小板≥50000/μl)福坦替尼组10例(45%)vs 安慰剂组0例(p=0.006)。
  • 福坦替尼组患者救援药物使用更少,出血症状更少。
  • 观察到的不良事件为轻至中度且可控,未发现新的安全性信号。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved for the treatment of chronic primary immune thrombocytopenia (ITP) in the United States, Canada and some European countries. We conducted a phase 3, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of fostamatinib in Japanese patients with primary ITP. Thirty-four patients were randomised to fostamatinib (n = 22) or placebo (n = 12) at 100-150 mg twice a day for 24 weeks. Stable responses (platelet ≥50 000/μl at ≥4 of the 6 visits from weeks 14 to 24) were observed in eight (36%) patients on fostamatinib and in none of the patients on placebo (p = 0.030). Overall responses (platelet ≥50 000/μl at ≥1 of the 6 visits from weeks 2 to 12) were seen in 10 (45%) patients on fostamatinib and in none of the patients on placebo (p = 0.006). Patients on fostamatinib required rescue medication less often and experienced fewer bleeding symptoms than patients on placebo. Adverse events observed were mild or moderate and were manageable. No new safety signals were identified in Japanese patients with ITP.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kuwana M, Ito T, Kowata S, et al. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study. Br J Haematol. 2022. PMID: 36470677. doi:10.1111/bjh.18582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。